At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 628 enrolled
Drug / intervention
LCI699 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension
In Brief
A Phase 2 clinical trial evaluating LCI699, Eplerenone, and 2 other interventions for Essential Hypertension. Completed, enrolled 628 participants across 1 site.
Detailed Summary
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartSep 11, 2008
Primary CompletionJul 2, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.8 years ago
Interventions
LCI699drug
LCI699 oral capsules
Eplerenonedrug
Eplerenone oral capsules
LCI699-matching Placebodrug
LCI699-matching placebo oral capsules
Eplerenone-matching Placebodrug
Eplerenone-matching placebo oral capsules